Tenaya Therapeutics, Inc.TNYANASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

defenseworld.net

Critical Analysis: Tenaya Therapeutics (NASDAQ:TNYA) vs. Corvus Pharmaceuticals (NASDAQ:CRVS)

Corvus Pharmaceuticals (NASDAQ: CRVS - Get Free Report) and Tenaya Therapeutics (NASDAQ: TNYA - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations. Institutional and Insider Ownership 46.6% of Corvus

globenewswire.com

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM

benzinga.com

Tenaya Stock Plunges After $60 Million Equity Offering

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) stock is trading lower on Friday, with a session volume of 42.39 million compared to the average volume of 3.51 million as per data from Benzinga Pro.

globenewswire.com

Tenaya Therapeutics Announces Pricing of Public Offering

seekingalpha.com

Tenaya Therapeutics, Inc. (TNYA) Discusses Initial Data From RIDGE-1 Phase Ib/II Trial of TN-401 Gene Therapy for ARVC Prepared Remarks Transcript

globenewswire.com

Tenaya Therapeutics Announces Proposed Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and warrants to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pre-funded warrants to purchase shares of common stock at a purchase price of $0.001 per share and warrants to purchase shares of common stock. The pre-funded warrants will be immediately exercisable and will not expire. All of the securities in this offering will be sold by Tenaya. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

globenewswire.com

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with More Than Six Months of Follow-Up Tenaya Management to Host a Webcast Conference Call Thursday, December 11 at 5:00 pm ET to Review Preliminary Results SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced interim data from the ongoing RIDGE™-1 Phase 1b/2 clinical trial of TN-401 gene therapy for the potential treatment of adults with arrhythmogenic right ventricular cardiomyopathy (ARVC), a form of arrhythmogenic cardiomyopathy (ACM) that primarily impacts the right ventricle, caused by mutations in the plakophilin-2 gene, PKP2.

globenewswire.com

Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy

MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with Sites MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with Sites

seekingalpha.com

Tenaya Therapeutics, Inc. (TNYA) Shareholder/Analyst Call Transcript

Tenaya Therapeutics, Inc. ( TNYA ) Shareholder/Analyst Call November 10, 2025 8:00 AM EST Company Participants Michelle Corral - Vice President of Investor Relationship & Corporate Communications Faraz Ali - CEO, Interim Principal Financial Officer & Director Whittemore G. Tingley - Chief Medical Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co., Research Division Michael Ulz - Morgan Stanley, Research Division Sara Nik - H.C.

globenewswire.com

Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201 Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Transduction and MyBP-C Protein Expression Completed Dosing in Cohort 2 of RIDGE-1 Trial of TN-401 for PKP2-associated ARVC; Cohort 1 Data On Track for Fourth Quarter Company Presentation Tenaya Management to Review New MyPEAK-1 Data on Webcast Call for Analysts and Investors Today at 8:00 a.

globenewswire.com

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research

globenewswire.com

Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™ -1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy

globenewswire.com

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference on Tuesday, October 14, 2025. Company management will host virtual 1x1 meetings on Wednesday, October 15, 2025.

globenewswire.com

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in the following October investor and industry conferences. Details are below:

globenewswire.com

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 202,000 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options have an exercise price of $1.20 per share, which is equal to the closing price of Tenaya's common stock on September 15, 2025. Each stock option has a ten-year term and vests as follows over a total of four years: 1/4th of the original number of shares subject to the stock option shall vest on the one-year anniversary of the employee's date of hire and 1/48th of the original number of shares subject to the stock option shall vest every month thereafter, subject to such employee's continued service with Tenaya on each such date.

seekingalpha.com

Tenaya Therapeutics, Inc. (TNYA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Tenaya Therapeutics, Inc. (NASDAQ:TNYA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT Company Participants Faraz Ali - CEO, Interim Principal Financial Officer & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst Okay. Great. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.

globenewswire.com

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 pm ET.

globenewswire.com

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants

globenewswire.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at 11:30 am ET.

fool.com

Tenaya (TNYA) Q2 Loss Narrows 59%

Tenaya Therapeutics (TNYA -2.99%), a clinical-stage biotechnology company focused on genetic therapies for heart disease, released second-quarter results on August 6, 2025. Tenaya posted a net loss per share of $(0.14) (GAAP) for Q2 2025, narrower than the $(0.19) loss analysts had predicted.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance